Logo
CustomersBlogPricingDemo
SIGN UP NOWBOOK A DEMO

What is the Fiscal Year for Ovid Therapeutics?

Date: November 13, 2026


Ovid Therapeutics's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.

Current Fiscal Year Overview

Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026

Quarterly Breakdown

Q1

Jan 1, 2026 – Mar 31, 2026

Q2

Apr 1, 2026 – Jun 30, 2026

Q3

Jul 1, 2026 – Sep 30, 2026

Q4

Oct 1, 2026 – Dec 31, 2026

Company Information

Headquarters

New York, New York

Industry

Biotechnology Research

Stock Symbol

OVID

Website
https://ovidrx.com
Description

Ovid Therapeutics is a biopharmaceutical company striving to calm the storm that causes seizures by developing new medicines for epilepsies and brain conditions. For those who need relief, we must succeed—their hopes are our aspirations. We act with urgency, ingenuity and integrity as we seek a future free of seizures. At Ovid, we are pursuing small molecule compounds with untapped potential. Applying our nimble, proven approach to accelerate clinical development, we aim to translate our molecules into first-in-class or best-in-class medicines. The patient, clinician and academic communities are our collaborators in every step of development from bench to bedside. Our accomplished team holds a track record of success in making medicines for rare diseases and neurology. Our goal is bold for the communities we serve. For more information, please visit www.ovidrx.com. Review our community guidelines: http://www.ovidrx.com/community-guidelines/


Use Salesmotion for Account Data and Insights

Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Ovid Therapeutics and uncover key business information that drives smarter conversations.

Book a demo today to strengthen your sales strategy with powerful data and actionable insights.

BOOK A DEMO